安索亚宁通过Nrf2-依赖机制改善线粒体功能,减轻肺动脉高血压和相关心力衰竭
Xiao Liu1, Xiaoli Tan1, Yidan Su1
1Department of Cardiology, Bishan Hospital of Chongqing Medical University, Chongqing, China.
概括
安索亚宁治疗通过增强线粒体功能,改善了肺动脉高血压 (PAH) 和右心力衰竭. 这种保护作用通过一个依赖Nrf2的通路进行介导,这表明安东素是PAH的潜在新疗法.
科学领域:
- 心血管研究研究心血管研究
- 线粒体生物学 线粒体生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺动脉高血压 (PAH) 涉及肺血管内皮细胞中的线粒体功能障碍.
- 众所周知,安托西亚宁可以保护线粒体功能,但它们在PAH预防中的作用尚未被探索.
研究的目的:
- 调查安东素在预防PAH方面的潜力,并阐明其潜在机制.
- 检查动物PAH模型中安东素对血液动力学,组织病理学和内皮功能的影响.
主要方法:
- 动物PAH模型是由21天的慢性缺氧诱导的.
- 动物接受了21天的安托西亚尼治疗.
- 评估了血液动力学,组织病理学,内皮功能,线粒体功能和Nrf2通路激活.
主要成果:
- 在PAH模型中,安托西亚宁治疗改善了肺内皮功能,减少了血管重塑,并缓解了右心力衰竭.
- 安索亚宁促进了Nrf2的核转位,增强了线粒体功能.
- 抑制Nrf2或Nrf2缺乏消除了安托素对PAH的保护作用.
结论:
- 安索亚宁通过依赖Nrf2的机制改善线粒体功能,减轻PAH和相关的右心力衰竭.
- 安索亚宁显示出作为肺动脉高血压新型治疗剂的潜力.
相关概念视频
Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
92
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
92
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
87
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
87
Mitochondria
8.9K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
8.9K
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291


